2018 Common Rule Updates
Summary
The Federal Policy for the Protection of Human Subjects or the “Common Rule” outlines specific regulations for human subjects research. The Common Rule is heavily based on the "The Belmont Report," but was revised by the HHS and FDA. The recent revisions to the Common Rule became effective January 21, 2019.
Full Description
2018 Common Rule Updates
The U.S. Department of Health and Human Services (HHS), Office for Human Research Protections (OHRP) and the Food and Drug Administration (FDA) oversee operations of the IRB.
Federal Regulation 45 CFR 46 Protection of Human Participants: applies to all research involving human participants conducted, supported, or otherwise subject to regulation by any Federal department or agency that takes appropriate administrative action to make the policy applicable to such research. Protection of Human Participants mandates research that involves human participants must be approved by an Institutional Review Board (IRB) to ensure the safety and the appropriate use of humans as participants in research studies.
- "To what does this policy apply?" (45 CFR 46.101)
- "General requirements for informed consent" (45 CFR 46.116)
Please see the US Department of Health and Human Services for more information.
| Revised Sections of The Common Rule | Summary of Changes | Timeline of Implementation |
|
Applicability |
46.101.(f)When applicable, American Indian and Alaska Native Tribal Laws will be applied. | January 21, 2019 |
|
Definitions |
46.102(e)-Definition of Human Subjects includes identifiable biospecimens. Identifiable human biospecimens and private information are treated similarly. 46.102(I)-Examples of what are not considered human subjects research. |
January 21, 2019 |
|
Assurance |
The elimination of the requirement that institutional review boards review grant applications or other funding proposals related to the research. | July 19, 2018 |
|
Exempt Research |
Exempt categories 1-2 and 5 are further defined, and 6 remains unchanged
|
January 21, 2019 |
|
IRB Review of Research |
46.109(a) - Exempt Research that require limited IRB review as a condition of exemption. Limited IRB Review is performed at an IRB Expedited Subcommittee meeting by an IRB Chair or an IRB Chair-designee. 46.109(f) - Continuing review is not required when Research eligible for expedited review, Research reviewed by the limited IRB review process, Research limited to only: data analysis, or accessing follow-up clinical data (performed as part of clinical care). |
January 21, 2019 |
|
Criteria for IRB Approval |
46.111(a)(3) & 46.111(b) - Vulnerable populations:Pregnant women and handicapped/mentally disabled populations are no longer considered vulnerable. Individuals with impaired decision-making capacity and economically/educational disadvantaged are considered vulnerable population. 46.11(a)(8) Approval criteria for a limited IRB review |
January 21, 2019 |
|
Cooperative Research |
This entire section has been revised. A brief summary is outlined below: 46.116(a) - New requirement of Key Information at the beginning of the consent form. 46.116(b) - One (1) new Basic element of informed consent. 46.116(c) - Three (3) new Additional elements of informed consent. 46.116(d) - Seven (7) elements of a Broad consent form. 46.116(f) - Revised criteria for a General Waiver or Alteration of Consent. 46.116(g) - New exception to Informed Consent: Screening, recruiting, determining eligibility is permitted under specific circumstances. 46.116(h) - A copy of the template consent form must be posted on a federal website after the clinical trial (sponsored by a federal department or agency) is closed to recruitment and no later than 60 days after the last study visit by any subject. DHHS guidance is forthcoming. |
January 20, 2020 |
|
Documentation of Informed Consent |
46.117(a) - Includes electronic format. 46.117(b) - Ensures that Key Information (i.e. concise summary) is presented first to the subject. |
January 21, 2019 |